Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  OSE Immunotherapeutics    OSE   FR0012127173

OSE IMMUNOTHERAPEUTICS

(OSE)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
04/12/2019 04/15/2019 04/16/2019 04/17/2019 04/18/2019 Date
4.11(c) 4.06(c) 4.01(c) 4.01(c) 4.05(c) Last
8 571 3 362 1 796 4 618 11 536 Volume
+0.98% -1.22% -1.23% 0.00% +1.00% Change
More quotes
Financials (EUR)
Sales 2019 18,3 M
EBIT 2019 4,90 M
Net income 2019 6,15 M
Finance 2019 12,1 M
Yield 2019 -
Sales 2020 3,33 M
EBIT 2020 -15,9 M
Net income 2020 -14,2 M
Debt 2020 0,39 M
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales2019 2,63x
EV / Sales2020 18,1x
Capitalization 60,0 M
More Financials
Company
Following the merger with Effimune, OSE Pharma changed its corporate name to OSE Immunotherapeutics. The new group specializes in the development of innovative treatments to activate or regulate the immune system and restore system disorders in the fields of immuno-oncology, autoimmune diseases and... 
More about the company
Surperformance© ratings of OSE Immunotherapeutics
Trading Rating : Investor Rating :
More Ratings
Latest news on OSE IMMUNOTHERAPEUTICS
04/11OSE Immunotherapeutics Announces Publication on Anti-IL-7 Receptor Antagonist..
GL
04/10OSE IMMUNOTHERAPEUTICS : Announces Issuance of Canadian Patent and Notice of All..
AQ
04/04OSE IMMUNOTHERAPEUTICS : Presents New Clinical and Preclinical Data on its Immun..
AQ
04/02OSE Immunotherapeutics Presents New Clinical and Preclinical Data on its Immu..
GL
03/28OSE Immunotherapeutics Reports 2018 Financial Results and Business Update
GL
03/26OSE Immunotherapeutics Announces New Research Collaboration with Léon Bérard ..
GL
03/07OSE Immunotherapeutics Presents its Novel Bispecific Checkpoint Inhibitor Pla..
GL
03/05OSE Immunotherapeutics Announces Clinical Trial Authorization for a Phase 1 b..
GL
03/01OSE IMMUNOTHERAPEUTICS : to Present New Clinical and Preclinical Data on its Imm..
AQ
02/28OSE IMMUNOTHERAPEUTICS : to Present New Clinical and Preclinical Data on its Imm..
AQ
More news
Sector news : Biotechnology & Medical Research - NEC
04/16GILEAD SCIENCES : Insitro to Collaborate on Nonalcoholic Steatohepatitis
DJ
04/15PATRICK THOMAS : Novartis Files Application for Macular Degeneration Treatment
DJ
04/12GILEAD SCIENCES : Novo Nordisk Plan NASH Collaboration
DJ
04/08GSK wins U.S. nod for two-drug HIV combination
RE
04/08Sanofi, Alnylam Complete Research Phase of Rare Disease Alliance
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart OSE IMMUNOTHERAPEUTICS
Duration : Period :
OSE Immunotherapeutics Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OSE IMMUNOTHERAPEUTICS
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 8,34 €
Spread / Average Target 106%
EPS Revisions
Managers
NameTitle
Alexis Peyroles Chief Executive Officer & Director
Dominique Costantini Chairman
Bernard Vanhove COO, Director-Research & Development
Anne-Laure Autret-Cornet Chief Financial Officer
Frédérique Corallo Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
OSE IMMUNOTHERAPEUTICS19.12%67
IQVIA HOLDINGS INC14.50%26 285
CELLTRION, INC.--.--%22 914
LONZA GROUP16.76%21 810
INCYTE CORPORATION16.31%15 847
EXACT SCIENCES CORPORATION46.13%11 596